Skip to content

Geron GERN Change in Other Assets

Change in Other Assets at other companies

Incyte logo
IncyteINCY
-$9.19M-115%
Immunome logo
ImmunomeIMNM
$5.1M+199%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$7.84M-30.8%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$3M
Tango Therapeutics logo
Tango TherapeuticsTNGX
-$10K-900%
Exelixis logo
ExelixisEXEL
-$58.65M-189%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$878.88M-8.6%
Enterprise value$964.15M-6.2%
P/S4.7×-172×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's change in other assets?
Geron (GERN) reported change in other assets of $2.23M in Q1 2026.
How has Geron's change in other assets changed year-over-year?
Geron's change in other assets increased by 32.3% year-over-year, from $1.69M to $2.23M.
What does change in other assets mean?
Change in miscellaneous assets affecting operating cash flow.